# Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI

Study · id `cardio:ct-nct01781715` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01781715](<https://clinicaltrials.gov/study/NCT01781715>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01781715

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT01781715. Randomized; no masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT01781715, source copy `cardio:ctgov-nct01781715-2013-02-01`, retrieved 2026-10-26)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01781715, source copy `cardio:ctgov-nct01781715-2013-02-01`, retrieved 2026-10-26)
- Primary completion: 2013-12 (anticipated) (ClinicalTrials.gov record NCT01781715, source copy `cardio:ctgov-nct01781715-2013-02-01`, retrieved 2026-10-26)
- Completion: 2014-12 (anticipated) (ClinicalTrials.gov record NCT01781715, source copy `cardio:ctgov-nct01781715-2013-02-01`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT01781715, source copy `cardio:ctgov-nct01781715-2013-02-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01781715-2013-02-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI
- Acronym: ZES for STEMI
- Condition: ST Elevation Myocardial Infarction, Multivessel Coronary Artery Disease
- Intervention (Device): Zotarolimus-eluting coronary stent
- Lead sponsor: Russian Academy of Medical Sciences
- Lead sponsor class: OTHER
- Collaborator: Medtronic
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Russian Academy of Medical Sciences (`cardio:org-russian-academy-of-medical-sciences`)
- Registry lists this organization as a collaborator: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: c7b4c2f45ba1a90d8adebe6ead2881b2efa7918be29c83f59fb4209bde8c4f58
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
